Drug or technology
3 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
JUL 1, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
This is an FDA supplemental approval action for acyclovir oral suspension labeling; it documents a regulatory decision, not clinical evidence of efficacy or safety.
JUN 24, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for acyclovir labeling update; clarifies product information but does not constitute clinical evidence of efficacy or safety.
JUN 24, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for acyclovir labeling update; this is a regulatory action record without clinical trial data or efficacy evidence.